Table 2.
Number of two doses of BNT162b2 and mRNA-1273 COVID-19 vaccine recipients, number of myocarditis and pericarditis cases after vaccination, and risk of myocarditis/pericarditis stratified on the interval between the first and second dose of vaccination among young population in Taiwan, March 22, 2021-Febuary 9, 2022.
| Interval between the first and second dose |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ≤28 days |
29–55 days |
56–83 days |
≥84 days |
|||||||||
| Age (years) | No. of cases | No. of people received vaccination | Risk per million vaccinees | No. of cases | No. of people received vaccination | Risk per million vaccinees | No. of cases | No. of people received vaccination | Risk per million vaccinees | No. of cases | No. of people received vaccination | Risk per million vaccinees |
| BNT162b2 vaccine | ||||||||||||
| Male | ||||||||||||
| 18-24 | 0 | 6575 | 0 | 4 | 278,761 | 14.35 (3.91–36.74) | 6 | 60,582 | 99.04 (36.35–215.57) | 2 | 56,138 | 35.63 (4.31–128.70) |
| 25-29 | 0 | 13,349 | 0 | 5 | 226,541 | 22.07 (7.17–51.51) | 0 | 15,473 | 0 | 0 | 6183 | 0 |
| Female | ||||||||||||
| 18-24 | 0 | 6268 | 0 | 4 | 300,974 | 13.29 (3.62–34.03) | 0 | 57,856 | 0 | 0 | 41,930 | 0 |
| 25-29 | 0 | 12,197 | 0 | 0 | 220,348 | 0 | 0 | 13,539 | 0 | 0 | 4682 | 0 |
| mRNA-1273 vaccine | ||||||||||||
| Male | ||||||||||||
| 18-24 | 0 | 1502 | 0 | 3 | 12,016 | 249.67 (51.49–729.63) | 0 | 6644 | 0 | 2 | 33,163 | 60.31 (7.30–217.85) |
| 25-29 | 0 | 2231 | 0 | 1 | 17,448 | 57.31 (1.45–319.33) | 3 | 8205 | 365.63 (75.40–1068.53) | 1 | 35,836 | 27.90 (0.71–155.48) |
| Female | ||||||||||||
| 18-24 | 0 | 3052 | 0 | 0 | 18,589 | 0 | 0 | 8903 | 0 | 0 | 23,577 | 0 |
| 25-29 | 0 | 5746 | 0 | 0 | 31,923 | 0 | 0 | 9953 | 0 | 0 | 28,378 | 0 |